论文部分内容阅读
将1992年6月～1994年3月来自欧洲12个中心的抗克罗米芬的促性腺激素正常的慢性无排卵妇女178例随机分组,重组促卵泡成熟激素(FSH;Puregon)组105例,尿促卵泡成熟激素(FSH;Metrodin)组67例。最多进行3个周期的治疗。促卵泡成熟激素(FSH)治疗在自发月经或孕酮(P)撤退出血后5d进行,低剂量渐增法,在第一个治疗周期每日肌注75IU(1安瓿)FSH最多14 d,如果没有卵泡≥12 mm或血清雌二醇(E_2)值明显升高,每周增加半安瓿直至卵泡发育完成的阈值剂量。每日最大量为3安瓿,治疗6周后停止用药。当1个卵泡直径≥18mm或2～3个卵泡直径达到15 mm时,肌注人绒毛膜促性腺激素(hCG)诱发排卵。
From June 1992 to March 1994 from 178 centers in Europe, anti-clomiphene citrate normal 178 cases of chronic anovulatory women were randomly divided into groups, recombinant follicle-stimulating hormone (FSH; Puregon) group of 105 cases of urinary urgency 67 cases of follicular mature hormone (FSH; Metrodin) group. Up to 3 cycles of treatment. Follicle-stimulating hormone therapy (FSH) was performed 5 days after withdrawal of spontaneous menstruation or progesterone (P) bleeding. The low dose escalation method was used. In the first treatment cycle, intramuscular injection of 75 IU (1 ampoule) No follicles ≥ 12 mm or serum estradiol (E_2) values were significantly increased weekly increase in semi-ampoule until the completion of the follicle development threshold dose. The maximum daily volume of 3 ampules, stop treatment after 6 weeks of treatment. When a follicle diameter ≥ 18mm or 2-3 follicles up to 15 mm in diameter, intramuscular injection of human chorionic gonadotropin (hCG) induced ovulation.